autologous blood and marrow transplantation - Blog Science ...

288 Chapter 6: Breast Cancer
Cancer. As was the whole PEGASE program, this work is supported by the French
Federation of Anti-cancer Center (FNCLCC). Additional grants were given by
Amgen France, Pharmacia-Upjohn, and Wyeth-Lederle.
The authors thank the other investigators who participated in the study: J.P.
Labat (Brest), C. Linassier (Tours), B. Audhuy (Comar), F. Feuilhade (Créteil),
B. Costa (Reims), R. Delva (Angers), H. Curé (Clermont-Ferrand), F. Rousseau
(Pontoise), A. Guillot (Saint-Etienne), M. Mousseau (Grenoble), and J.M.
Ferrero (Nice). They also thank the Department of Biostatistics of the Institute
Curie and specially B. Asselain and M. Barrand for their help in collecting and
analyzing data.
REFERENCES
1. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: A review. J Clin
Oncol 10:1014-1024, 1992.
2. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors,
ed. 4. New York: Springer-Verlag, 1988.
3. Swain SM, Lippman ME: Treatment of patients with inflammatory breast cancer. In: De
Vita VT Jr, Hellman S, Rosenberg SA (eds) Important Advances in Oncology.
Philadelphia: Lippincott, 1989, p. 129-150.
4. Rouessé J, Friedman S, Sarrazin D, et al.: Primary chemotherapy in the treatment of
inflammatory breast carcinoma: A study of 230 cases from the institut Gustave-Roussy.
J Clin Oncol 4:1765-1771, 1986.
5. Koh EH, Buzdar AU, Ames FC, et al.: inflammatory carcinoma of the breast: Results of
a combined-modality approach—M.D. Anderson Cancer Center experience. Cancer
Chemother Pharmacol 27:94-100, 1990.
6. Pisansky TM, Schaid DJ, Loprinzi CL, et al.: Inflammatory breast cancer: Integration of
irradiation, surgery and chemotherapy. Am J Clin Oncol 15:376-387, 1992.
7. Bauer RL, Busch E, Levine E, et al.: Therapy for inflammatory breast cancer: Impact of
doxorubicin-based therapy. Ann Surg Oncol 2:288-294, 1995.
8. Chevallier B, Asselain B, Kunlin A, et al.: Inflammatory breast cancer: Determination of
prognostic factors by univariate and multivariate analysis. Cancer 60:897-902, 1987.
9. Palangie T, Mosseri V, Mihura J, et al.: Prognostic factors in inflammatory breast cancer
and therapeutic implications. Eur J Cancer 30A:921-927, 1994.
10. Feldman LD, Hortobagyi GN, Buzdar AU, et al.: Pathological assessment of response to
induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986.
11. Noguchi S, Miyauchi K, Nishizawa Y, et al.: Management of inflammatory carcinoma
of the breast with combined modality therapy including intraarterial infusion chemother­
apy as an induction therapy. Long-term follow-up results of 28 patients. Cancer
61:1483-1491, 1988.
12. Maloisel F, Dufour P, Bergerat JP, et al.: Results of initial doxorubicin, 5- fluorouracil,
and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the
breast. Cancer 65:851-855, 1990.
13. Armstrong DK, Fetting JH, Davidson NE, et al.: Sixteen week dose intense chemother-